today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom. Jasper will present initial clinical ...

Selected plenary presentation highlights positive Phase 3 SURPASS-ET clinical trial results of ropeginterferon alfa-2b-njft for the treatment of essential thrombocythemia (ET) Additional oral ...

The Pearl, a “milestone” project, will be home to Charlotte’s first four-year medical school and innovative STEM work.

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a ...

(MENAFN- GlobeNewsWire - Nasdaq) Recently disclosed clinical cohort data from high ... (CNS), today announced details for three oral presentations reviewing recent updates supporting its TSHA ...

(“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today ...

The three presentations will also be presented during a poster session on Monday, June 9, 2025, from 5:00-7:00 PM EST. Additional details on the meeting can be found at IRSF’s website. “We are excited ...

These encouraging results suggest the potential of IBI343 in this challenging-to-treat malignancy. Supported by these robust clinical findings, IBI343 has been granted Breakthrough Therapy Designation ...

Circulating tumor DNA (ctDNA) testing has the potential to dramatically impact our approach to cancer management. This minimally invasive test, with potential for repeated testing, can track dynamic ...